Invesaro

Stocks DRUG Financial statements

Financial statements

BRIGHT MINDS BIOSCIENCES INC. financial statements

Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data BRIGHT MINDS BIOSCIENCES INC. files with the SEC in its annual reports.

In CAD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2021FY2021FY2022FY2023FY2024
Research and development0.356.3112.251.18
Income tax00000
Net income-0.48-8.65-15-7.37-2.8
EPS, basic-0.65-4.82-6.06-1.98-0.65
EPS, diluted-0.65-4.82-6.06-1.98-0.65

Balance sheet

FY2021FY2021FY2022FY2023FY2024
Cash and equivalents0.819.811.66.755.72
Total current assets0.882011.96.815.99
Lease right-of-use assets00.140.070.12
Total assets0.882012.16.886.1
Accounts payable0.150.641.40.210.45
Total current liabilities0.641.470.280.53
Lease liabilities00.0700.04
Total liabilities0.150.641.540.280.57
Retained earnings-0.56-9.21-24.2-31.5-34.3
Total equity0.7319.410.56.65.54
Total liabilities and equity0.882012.16.886.1

Cash flow statement

FY2021FY2021FY2022FY2023FY2024
Net income-0.48-8.65-15-7.37-2.8
Cash from operations-0.29-7.32-13.6-7.02-1.85
Stock issued1.0127.7
Cash from financing1.0126.15.22.190.81
Exchange rate effect00.220.26-0.050.01
Net change in cash0.7218.7-8.39-4.83-1.04

Key metrics

Worked out from the statements above. Latest values use fiscal 2024. No valuation: the share price is quoted in a different currency than the statements.

Profitability

MetricValueHow it is calculated
Return on assets (ROA)-43.2%Net income / average total assets.

Growth

MetricValueHow it is calculated
Total assets growth, 1y-11.3%Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y-32.7%Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.

Balance sheet health

MetricValueHow it is calculated
Current ratio11.3xCurrent assets / current liabilities.
Quick ratio10.8x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio10.8x(Cash + short-term investments) / current liabilities.
Liabilities / assets9.3%Total liabilities / total assets.
Working capitalCA$5.5MCurrent assets - current liabilities.

Per share

MetricValueHow it is calculated
EPS, diluted-CA$0.65Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic-CA$0.65Net income per basic share, as reported (split-adjusted).
Was BRIGHT MINDS BIOSCIENCES INC. profitable in fiscal 2024?

No. It reported a net loss of CA$2.8M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to BRIGHT MINDS BIOSCIENCES INC.